Prevention of Post-Operative Cardiac Arrhythmias (POCA)
Cardiac; Dysrhythmia, Postoperative, Congenital Heart Surgery
About this trial
This is an interventional treatment trial for Cardiac; Dysrhythmia, Postoperative focused on measuring Magnesium Sulfate, Dexedetomidine, anti-arrhythmic medications
Eligibility Criteria
Inclusion Criteria:
- 1) Any infant, child, adolescent, or young adult with congenital or acquired heart disease undergoing open heart surgical repair using cardiopulmonary bypass is eligible to be enrolled in this trial.
- 2) No age, gender or ethnic group restrictions.
Exclusion Criteria:
- 1) Non-cardiopulmonary bypass repair of a congenital or acquired cardiac defect.
- 2) Significant pre-operative arrhythmia history
- 3) Past history of adverse effect to any of the study medication agents
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Active Comparator
Active Comparator
Active Comparator
Active Comparator
Stage 1, Group 1 - Dexmedetomidine
Stage 1, Group 2- Magnesium
Stage 2, AMIODARONE
Stage 2, PROCAINAMIDE
Dexmedetomidine: 1 mcg/kg administered at end of cardiopulmonary bypass, followed by a 0.5 mcg/kg/h infusion for 72 h postoperatively or ready for extubation prior to 72 hour time period
Magnesium Sulfate (50 mg/kg) bolus administered at the time of Aortic Cross Clamp Release, with continued administration for 72 hours postoperatively at a dose of 30 mg/kg/day.
AMIODARONE I V Amiodarone 2.5 mg/kg administered over 30 minutes Second 2.5 mg/kg dose if needed over 30 minutes Continuous Intravenous Infusion 10-15 mg/kg/24 hours
PROCAINAMIDE IV Procainamide 10-15 mg/kg administered over 45 minutes Continuous Intravenous Infusion 20-50 mcg/kg/min